These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1638500)

  • 1. Cytohematologic and cytogenetic prognostic factors at diagnosis and in the evolution in 46 primary myelodysplastic syndromes.
    González Manso AI; García Marcilla A; Barreiro E; Gilsanz F
    Cancer Genet Cytogenet; 1992 Jul; 61(2):174-82. PubMed ID: 1638500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnosis and prognosis in myelodysplastic syndromes. The impact of cytogenetics].
    Mecucci C
    Recenti Prog Med; 2014 Mar; 105(3):110-4. PubMed ID: 24675452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome.
    Valcárcel D; Ademà V; Solé F; Ortega M; Nomdedeu B; Sanz G; Luño E; Cañizo C; de la Serna J; Ardanaz M; Marco V; Collado R; Grau J; Montoro J; Mallo M; Vallespí T
    J Clin Oncol; 2013 Mar; 31(7):916-22. PubMed ID: 23319689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations.
    Tricot G; Boogaerts MA; De Wolf-Peeters C; Van den Berghe H; Verwilghen RL
    Br J Haematol; 1985 Apr; 59(4):659-70. PubMed ID: 3857071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis.
    Neukirchen J; Lauseker M; Hildebrandt B; Nolting AC; Kaivers J; Kobbe G; Gattermann N; Haas R; Germing U
    Cancer; 2017 Dec; 123(23):4608-4616. PubMed ID: 28746789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
    Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
    Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cytogenetic study of 93 myelodysplastic syndromes].
    Solé F; Woessner S; Florensa L; Pérez-Losada A; Acín P; Besses C; García-Eroles L; Sans-Sabrafen J
    Med Clin (Barc); 1998 Jan; 110(3):94-8. PubMed ID: 9534140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiplex ligation-dependent probe amplification assay identifies additional copy number changes compared with R-band karyotype and provide more accuracy prognostic information in myelodysplastic syndromes.
    Wang J; Ai X; Qin T; Xu Z; Zhang Y; Liu J; Li B; Fang L; Zhang H; Pan L; Hu N; Qu S; Cai W; Ru K; Jia Y; Huang G; Xiao Z
    Oncotarget; 2017 Jan; 8(1):1603-1612. PubMed ID: 27906673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
    Falantes JF; Calderón C; Márquez Malaver FJ; Alonso D; Martín Noya A; Carrillo E; Martino ML; Montero I; González J; Parody R; Espigado I; Pérez-Simón JA
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):144-52. PubMed ID: 23137720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of chromosome karyotype between myelodysplastic syndrome and acute leukemia patients confirmed at the same period].
    Jiang M; Wen BZ; Li L; Chen S; Cheng H; Hao JP; Chen R; Wang L; Zhao F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):387-92. PubMed ID: 24763010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes.
    Solé F; Luño E; Sanzo C; Espinet B; Sanz GF; Cervera J; Calasanz MJ; Cigudosa JC; Millà F; Ribera JM; Bureo E; Marquez ML; Arranz E; Florensa L
    Haematologica; 2005 Sep; 90(9):1168-78. PubMed ID: 16154839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis.
    Tricot G; Vlietinck R; Boogaerts MA; Hendrickx B; De Wolf-Peeters C; Van den Berghe H; Verwilghen RL
    Br J Haematol; 1985 May; 60(1):19-32. PubMed ID: 3859319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytogenetic characteristics of patients with signs and symptoms of myelodysplastic syndromes in the State of Pará, Brazil.
    Pinto GR; Overal DJ; Moraes LS; Van Den Berg AV; Lemos JA; Smith Mde A; Burbano RR
    Genet Mol Res; 2005 Mar; 4(1):18-30. PubMed ID: 15841432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine.
    Sébert M; Komrokji RS; Sekeres MA; Prebet T; Cluzeau T; Santini V; Gyan E; Sanna A; Ali NH; Hobson S; Eclache V; List A; Fenaux P; Adès L
    Leuk Res; 2017 Dec; 63():72-77. PubMed ID: 29112938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and prognostic significance of cytogenetics in adult primary myelodysplastic syndromes.
    Jotterand M; Parlier V
    Leuk Lymphoma; 1996 Oct; 23(3-4):253-66. PubMed ID: 9031106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapse and cytogenetic evolution in myeloid neoplasms.
    Ertz-Archambault N; Kelemen K
    Panminerva Med; 2017 Dec; 59(4):308-319. PubMed ID: 29144072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytogenetic evolution correlates with poor prognosis in myelodysplastic syndrome.
    Wang H; Wang XQ; Xu XP; Lin GW
    Cancer Genet Cytogenet; 2010 Jan; 196(2):159-66. PubMed ID: 20082852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematologic and cytogenetic analyses of 99 cases of de novo myelodysplastic syndromes.
    D'Emilio A; Montaldi A; Stella M; Celli P; Guercini N; Tremul L; Rodeghiero F
    Haematologica; 1993; 78(6 Suppl 2):61-5. PubMed ID: 8039762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The myelodysplastic syndromes: analysis of prognostic factors and comparison of prognostic systems in 128 Chinese patients from a single institution.
    Zhao WL; Xu L; Wu W; Yan H; Tang W; Hu J; Chen Y; Li JM; Zeng XY; Xiong SM; Shen ZX; Chen Z; Wang ZY; Chen SJ
    Hematol J; 2002; 3(3):137-44. PubMed ID: 12111649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.
    van Spronsen MF; Ossenkoppele GJ; Westers TM; van de Loosdrecht AA
    Eur J Cancer; 2016 Mar; 56():10-20. PubMed ID: 26798967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.